Form 4: Artiva CMO Sells Shares for Tax Obligations

Artiva Biotherapeutics Chief Medical Officer Subhashis Banerjee sold 7,037 shares to cover tax liabilities following the vesting of restricted stock units.

Summary

• Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc., disposed of 7,037 shares of common stock on May 19, 2026.
• The shares were sold at a weighted average price of $9.0076, with individual transaction prices ranging from $8.7404 to $9.0104.
• The total value of the transaction was approximately $63,386.
• This sale was non-discretionary and conducted under a 'sell-to-cover' policy to satisfy tax withholding obligations related to the vesting and release of restricted stock units (RSUs).
• Following the transaction, Banerjee directly owns 144,963 shares of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sale was non-discretionary and purely for tax withholding, while the executive maintains a significant long-term equity position.

Positives

• The reporting person retains a substantial direct ownership stake of 144,963 shares.
• The sale was non-discretionary, meaning it does not reflect a lack of confidence in the company's future by the executive.
• The transaction was part of a pre-established 'sell-to-cover' policy for tax compliance.

Negatives

• Insider selling, regardless of the reason, reduces the total equity alignment between management and shareholders.
• The sale occurred at a price point near the lower end of the reported daily range ($8.7404).

Risks

• Future automatic sales for tax purposes may create minor downward pressure on the stock price during vesting periods.
• Public perception of insider sales can sometimes be misinterpreted by the market as a negative signal despite the non-discretionary nature.

Future Outlook

No specific forward-looking guidance or strategic updates were provided in this routine regulatory filing.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a standard administrative procedure in the biotechnology and broader tech sectors to manage the tax impact of equity-based compensation for high-level executives.

Comparison to Industry Standards

• The use of a 'sell-to-cover' policy is consistent with practices at peer clinical-stage biopharmaceutical companies such as Fate Therapeutics and Nkarta.
• The executive's remaining stake is within the typical range for a C-suite officer in a mid-cap biotechnology firm.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact as the sale volume is low relative to total shares outstanding and was non-discretionary.
• Management: The CMO successfully met tax obligations while retaining over 95% of his prior direct holding.

Next Steps

• Monitor future Form 4 filings for additional RSU vesting dates and associated sell-to-cover transactions.

Key Dates

Recommendation

The filing represents a routine administrative transaction for tax purposes and does not provide new material information regarding the company's clinical pipeline or financial runway that would warrant a change in investment thesis.

Keywords

Artiva Biotherapeutics, ARTV, Insider Trading, Form 4, Chief Medical Officer, Subhashis Banerjee, Sell-to-Cover, Restricted Stock Units, Biotechnology